FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979752810> ?p ?o ?g. }

• W2979752810 abstract "Abstract Chronic lymphocytic leukemia (CLL) is a disease characterized by the monoclonal accumulation of well-differentiated CD5 B cells. Previously, we reported that CLL cells that use unmutated immunoglobulin VH (IgVH) genes and/or express ZAP-70 are more responsive to signaling induced by ligation of surface IgM compared to cells that use mutated IgVH and lack expression of ZAP-70 (Chen et al. Blood 2005) Because signaling through the Ig receptor appears to play a role in the pathogenesis or progression of CLL, targeting the Ig signal transduction pathway in CLL might have therapeutic utility, particularly for those patients with high-risk disease. Dasatinib (Sprycel) is a tyrosine kinase inhibitor (TKI) with antiproliferative activity against hematological and solid tumor cell lines and it is FDA approved for the treatment of patients with CML and Ph+ ALL. Contrary to Imatinib (Gleevec), Dasatinib is a potent TKI not only of the Abl family of kinases but also of Src kinases, which regulate Ig-receptor signal transduction and govern the early events following Ig receptor ligation. Because Dasatinib TKI profile and its potential role inhibiting BCR signaling we studied its in vitro activity in CLL. Primary leukemia cells from 40 different CLL patients were evaluated. We found that Dasatinib, but not Imatinib, induced apoptosis in CLL cells at doses that were pharmacologically achievable. The IC50 for Dasatinib was in the 30–100 nM range. Interestingly, the pro-apoptotic activity of Dasatinib in CLL cells was not observed in normal B, T cells or blood mononuclear cells of healthy donors, suggesting that Dasatinib has a specific effect on CLL cells. Dasatinib induced apoptosis in CLL cells in a time and concentration dependent manner. Peak apoptosis occurred after 2 hours of in vitro exposure. Leukemia cells that expressed ZAP-70 were significantly more sensitive to Dasatinib-induced apoptosis than CLL cells lacking expression of ZAP-70. In addition, Dasatinib enhanced in vitro the pro-apoptotic activity of Rituximab and Fludarabine in CLL cells. Dasatinib treatment of CLL cells induced changes in the expression profile of apoptosis related genes as well as changes in apoptosis related proteins such as cleavage of PARP-1 and Caspases. Moreover, CLL cells treated in vitro with Dasatinib showed reduced tyrosine kinase activity measured by ELISA and also by immunoblots of CLL-cell lysates using specific phospho-TK antibodies. In addition, Ig receptor signaling following surface IgM ligation was decreased in CLL cells that were pre-treated with Dasatinib relative to that of untreated CLL cells. In conclusion, Dasatinib induces apoptosis of CLL cells at low nanomolar concentrations that do not appear to affect the viability of B cells, T cells, or blood mononuclear cells of healthy adults. CLL cells that expressed ZAP-70 were significantly more sensitive to Dasatinib than CLL cells that lacked expression of ZAP-70. This process was associated with impairment of BCR signaling, decrease TK activity and regulation of genes and proteins related to apoptosis. In addition, treatment of CLL cells with Dasatinib enhanced the in vitro activity of Rituximab and Fludarabine. These results reveal that Dasatinib is potentially active in CLL, providing a rationale for clinical trials evaluating its clinical activity in the treatment of patients with this disease." @default.
• W2979752810 created "2019-10-18" @default.
• W2979752810 creator A5013814515 @default.
• W2979752810 creator A5016512960 @default.
• W2979752810 creator A5032101078 @default.
• W2979752810 creator A5036828560 @default.
• W2979752810 creator A5060250070 @default.
• W2979752810 creator A5081896361 @default.
• W2979752810 date "2007-11-16" @default.
• W2979752810 modified "2023-09-26" @default.
• W2979752810 title "Dasatinib Induces Apoptosis in Chronic Lymphocytic Leukemia and Enhances the Activity of Rituximab and Fludarabine." @default.
• W2979752810 doi "https://doi.org/10.1182/blood.v110.11.1116.1116" @default.
• W2979752810 hasPublicationYear "2007" @default.
• W2979752810 type Work @default.
• W2979752810 sameAs 2979752810 @default.
• W2979752810 citedByCount "2" @default.
• W2979752810 crossrefType "journal-article" @default.
• W2979752810 hasAuthorship W2979752810A5013814515 @default.
• W2979752810 hasAuthorship W2979752810A5016512960 @default.
• W2979752810 hasAuthorship W2979752810A5032101078 @default.
• W2979752810 hasAuthorship W2979752810A5036828560 @default.
• W2979752810 hasAuthorship W2979752810A5060250070 @default.
• W2979752810 hasAuthorship W2979752810A5081896361 @default.
• W2979752810 hasConcept C126322002 @default.
• W2979752810 hasConcept C170493617 @default.
• W2979752810 hasConcept C203014093 @default.
• W2979752810 hasConcept C2776694085 @default.
• W2979752810 hasConcept C2776755627 @default.
• W2979752810 hasConcept C2777583451 @default.
• W2979752810 hasConcept C2777938653 @default.
• W2979752810 hasConcept C2778461978 @default.
• W2979752810 hasConcept C2778729363 @default.
• W2979752810 hasConcept C2779263901 @default.
• W2979752810 hasConcept C2779536868 @default.
• W2979752810 hasConcept C3019892230 @default.
• W2979752810 hasConcept C42362537 @default.
• W2979752810 hasConcept C502942594 @default.
• W2979752810 hasConcept C62478195 @default.
• W2979752810 hasConcept C71924100 @default.
• W2979752810 hasConcept C86803240 @default.
• W2979752810 hasConcept C90059517 @default.
• W2979752810 hasConcept C95444343 @default.
• W2979752810 hasConceptScore W2979752810C126322002 @default.
• W2979752810 hasConceptScore W2979752810C170493617 @default.
• W2979752810 hasConceptScore W2979752810C203014093 @default.
• W2979752810 hasConceptScore W2979752810C2776694085 @default.
• W2979752810 hasConceptScore W2979752810C2776755627 @default.
• W2979752810 hasConceptScore W2979752810C2777583451 @default.
• W2979752810 hasConceptScore W2979752810C2777938653 @default.
• W2979752810 hasConceptScore W2979752810C2778461978 @default.
• W2979752810 hasConceptScore W2979752810C2778729363 @default.
• W2979752810 hasConceptScore W2979752810C2779263901 @default.
• W2979752810 hasConceptScore W2979752810C2779536868 @default.
• W2979752810 hasConceptScore W2979752810C3019892230 @default.
• W2979752810 hasConceptScore W2979752810C42362537 @default.
• W2979752810 hasConceptScore W2979752810C502942594 @default.
• W2979752810 hasConceptScore W2979752810C62478195 @default.
• W2979752810 hasConceptScore W2979752810C71924100 @default.
• W2979752810 hasConceptScore W2979752810C86803240 @default.
• W2979752810 hasConceptScore W2979752810C90059517 @default.
• W2979752810 hasConceptScore W2979752810C95444343 @default.
• W2979752810 hasLocation W29797528101 @default.
• W2979752810 hasOpenAccess W2979752810 @default.
• W2979752810 hasPrimaryLocation W29797528101 @default.
• W2979752810 hasRelatedWork W1991795177 @default.
• W2979752810 hasRelatedWork W2016014103 @default.
• W2979752810 hasRelatedWork W2100041900 @default.
• W2979752810 hasRelatedWork W2556047608 @default.
• W2979752810 hasRelatedWork W2580856344 @default.
• W2979752810 hasRelatedWork W2593079649 @default.
• W2979752810 hasRelatedWork W2620094379 @default.
• W2979752810 hasRelatedWork W2979743675 @default.
• W2979752810 hasRelatedWork W2979752810 @default.
• W2979752810 hasRelatedWork W4200265697 @default.
• W2979752810 isParatext "false" @default.
• W2979752810 isRetracted "false" @default.
• W2979752810 magId "2979752810" @default.
• W2979752810 workType "article" @default.